ALTANA Pharma Submits Daxas-R- -Roflumilast- for European Approval.Business Editors/Health/Medical Writers BAD HOMBURG, Germany--(BUSINESS WIRE)--Feb. 13, 2004 ALTANA AG (NYSE NYSE See: New York Stock Exchange :AAA AAA: see American Automobile Association. (Triple A) A common single-cell battery used in a myriad of electronic devices of all variety. Like its double A (AA) cousin, it provides 1.5 volts of DC power. When used in series, the voltage is multiplied. )(FWB:ALT) said today that its Pharmaceutical Division ALTANA Pharma has submitted the registration dossier for its respiratory drug Daxas(R) (Roflumilast) for European approval to the European Agency for the Evaluation of Medicinal Products (EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. ). Daxas(R) is being developed as an oral, once-daily, anti-inflammatory, selective phosphodiesterase-4 (PDE4)-inhibitor for the treatment of chronic obstructive pulmonary disease chronic obstructive pulmonary disease n. Abbr. COPD A chronic lung disease, such as asthma or emphysema, in which breathing becomes slowed or forced. (COPD COPD chronic obstructive pulmonary disease. COPD abbr. chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) ) and asthma. "COPD and asthma are severe diseases which are two of the most frequent causes of death. Therefore we are delighted that we have developed a new therapy which shall offer patients a safe and effective option to existing therapies," said Dr. Hans-Joachim Lohrisch, Member of the Management Board of ALTANA AG and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of ALTANA Pharma. Daxas(R) is being developed with Pfizer Inc in the United States and other markets. A cooperation agreement has also been made with Tanabe Seiyaku in Japan. This press release may contain forward-looking statements, i.e., current estimates or expectations of future events or future results. These statements are based on beliefs of ALTANA's management as well as assumptions made by and information currently available to ALTANA. Many factors that ALTANA is unable to predict with accuracy could cause ALTANA's actual results or performance to be materially different from those that may be expressed or implied by such forward-looking statements. Forward-looking statements speak only as of the date they are made. ALTANA does not intend, and does not assume any obligation, to update forward-looking statements to reflect facts, circumstances or events that have occurred or changed after such statements have been made. This press release is also available on the Internet at www.altana.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion